Background: Migraine is a disabling primary headache disorder and metabolic syndrome is a major escalating public-health challenge worldwide. They share some common pathophysiology. But till date, their relationship is obscure. Methods: This study was conducted in headache clinic and inpatient-outpatient department of Neurology and Biochemistry laboratory of BSMMU, from June 2017 to February 2019. In these age-sex matched case control study, 30 migraine patient and equal number non migraine volunteer were taken according to inclusion exclusion criteria. Waist circumference (WC), blood pressure (BP), fasting plasma glucose (FPG), serum triglyceride (TG) and high density lipoprotein cholesterol (HDL-C) were measured among all. Results: In this case control study, 24 women and 6 men were taken in both case and control groups, with mean age (±SD) of 32 (±7.77) and 30 (±8.46) years respectively. Metabolic syndrome was significantly higher among migraineurs (36.7% in case and 13.3% in control group respectively, p=0.037). Patient with metabolic syndrome had 3.763 times more chance of having migraine then person without metabolic syndrome [p=0.037, OR=3.763, 95% C.I. (1.038-13.646)]. Conclusion: There is an association between metabolic syndrome and migraine. Bangladesh Journal of Neuroscience 2018; Vol. 34 (1): 17-24

Background: Epilepsy is a common chronic neurological disorder worldwide. Carbamazepine is one of the most commonly used antiepileptic drugs. It is a hepatic cytochrome P 450 enzyme inducer which is thought to cause alteration of serum lipids. Objective: To evaluate the effect of carbamazepine on serum cholesterol and atherogenic ratios in young adult epileptic patients. Materials and methods: This prospective study was conducted in the epilepsy clinic and Neurology OPD of Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, from December, 2017 to March, 2019. A total fifty seven newly diagnosed epileptic patients fulfilling the study criteria were studied. Serum TC, HDL-C, TG was measured by using Beckman Coulter- AU680 analyzer machine and LDL-C was calculated according to the Friedewald formula in the laboratory of Department of Biochemistry, BSMMU. Results: The mean (±SD) serum TC, LDL, TG, TC/HDL-C and LDL-C/HDL-C were significantly increased (p-value < 0.001) at 3 months of carbamazepine therapy in comparison to the baseline levels. The mean (±SD) serum HDL was decreased at 3 months of therapy which was not statistically significant (p-value: 0.135). Conclusion: Carbamazepine caused significant rise in serum TC, LDL-C, TG and atherogenic ratios (TC/HDL-C, LDL-C/HDL-C), and insignificant reduction in the serum HDL-C level after three months of therapy. Bangladesh Journal of Neuroscience 2018; Vol. 34 (1): 32-38